These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33403093)

  • 1. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
    Becnel MR; Lee HC
    Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat relapsed and/or refractory multiple myeloma.
    Lee HC; Cerchione C
    Hematol Rep; 2020 Sep; 12(Suppl 1):8955. PubMed ID: 33042504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
    Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
    Front Oncol; 2021; 11():678634. PubMed ID: 34046363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
    Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
    Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
    Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
    Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
    Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
    Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
    Cancer; 2024 Aug; 130(15):2629-2641. PubMed ID: 38630908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
    Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
    Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
    de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
    Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
    J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma.
    Ketchum EB; Clarke A; Clemmons AB
    J Adv Pract Oncol; 2022 Jan; 13(1):77-85. PubMed ID: 35173991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
    Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
    Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belantamab Mafodotin: First Approval.
    Markham A
    Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.